Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for diastolic function in obese adults with prediabetes
IRCT20220910055934N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in prediabetes, diastolic dysfunction and obesity comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Early peak velocity/Late peak velocity (E/A). Started Oct 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
prediabetesdiastolic dysfunctionobesity
Beyond the preview
Go deeper on IRCT20220910055934N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220910055934N1.